evoke semaglutide trial When GLP-1s become brain drugs evoke semaglutide trial Novo Nordisk's

Roche s collaboration with Zealand around petrelintide reflects a broader industry push toward amylin and combination obesity strategies beyond classic GLP-1 mechanisms

This process stimulates GLP-1 production, as gut bacteria ferment soluble fiber into short-chain fatty acids that further enhance GLP-1 secretion (Ld, 2025)

Common pharmacological treatments include antithyroid drugs such as propylthiouracil (PTU), methimazole (MMI), carbimazole, and levothyroxine (LT4) (Ling et al

Wegovy is administered as a once-weekly subcutaneous injection and has been shown in clinical trials to produce significant weight loss when combined with a reduced-calorie diet and increased physical activity